Effect of Hydrochlorothiazide on Urinary Calcium Excretion in Dent Disease: An Uncontrolled Trial

被引:41
作者
Blanchard, Anne [1 ,2 ]
Vargas-Poussou, Rosa [1 ,2 ,3 ]
Peyrard, Severine [1 ]
Mogenet, Agnes
Baudouin, Veronique [4 ]
Boudailliez, Bernard [5 ,6 ]
Charbit, Marina [1 ,2 ]
Deschesnes, George [4 ]
Ezzhair, Nadia
Loirat, Chantal [4 ]
Macher, Marie-Alice [4 ]
Niaudet, Patrick [2 ,4 ]
Azizi, Michel [1 ,2 ]
机构
[1] Hop Europeen Georges Pompidou, AP HP, Ctr Invest Clin, F-75015 Paris, France
[2] Univ Paris 05, Fac Med Paris Descartes, F-75270 Paris 06, France
[3] INSERM, U772, F-75654 Paris 13, France
[4] Univ Paris 07, Fac Med, F-75221 Paris 05, France
[5] Univ Picardie, AP HP, Fac Med, F-80025 Amiens, France
[6] Ctr Hosp Amiens Sud, Dep Nephrol Pediat, Amiens, France
关键词
Dent disease; nephrolithiasis; clinical trial; thiazides;
D O I
10.1053/j.ajkd.2008.08.021
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
hyponatremiaBackground: Thiazide doses equivalent to 1 to 2 mg/kg/d of hydrochlorothiazicle (HCTZ) have been proposed to correct hypercalciuria and prevent kidney failure in patients with Dent disease. However, they can cause adverse metabolic effects in the long term. In treating hypertension in children, lower thiazide doses have been shown to be as effective and well tolerated. Study Design: Uncontrolled trial, with forced-titration sequential open-label study design. Setting & Participants: 7 boys with genetically confirmed Dent disease and mild phenotype (neither overt sodium wasting nor kidney failure). Intervention: After a 1-month run-in period, patients sequentially received amiloride (5 mg/d) alone (1 month) and then for 3 periods of 2 months in association with increasing doses of HCTZ (< 0.2, 0.2 to 0.4, and 0.4 to 0.8 mg/kg/d). Outcomes: Urinary calcium excretion and extracellular volume indicators. Measurements: At the end of each period, 2 daily 24-hour urinary collections were performed on the days preceding admission. Blood and spot urine samples also were collected. Results: A greater HCTZ dose increased renin, aldosterone, and plasma protein concentrations. Amiloride alone had no effect on calcium excretion. The greatest HCTZ doses decreased spot urinary calcium excretion by 42% compared with baseline (median, 0.3; minimum, maximum, 0.2, 0.8 versus median, 0.8; minimum, maximum, 0.4, 1.1, respectively; P = 0.03). However, patients developed adverse reactions, including muscle cramps (n = 2), biological (n = 7) or symptomatic hypovolemia (n = 1), hypokalemia (n = 4), and hyponatremia (n = 1), which all corrected after treatment withdrawal. Limitation: Small sample size and absence of a control group. Conclusion: HCTZ doses greater than 0.4 mg/kg/d decreased calcium excretion, but were associated with significant adverse events. Thiazide diuretic therapy should be considered with caution in children with Dent disease.
引用
收藏
页码:1084 / 1095
页数:12
相关论文
共 35 条
[1]   PHARMACOKINETICS OF HYDROCHLOROTHIAZIDE IN MAN [J].
BEERMANN, B ;
GROSCHINSKYGRIND, M .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1977, 12 (04) :297-303
[2]  
BERGLUND G, 1976, ACTA MED SCAND, V199, P499
[3]   Paracellin-1 is critical for magnesium and calcium reabsorption in the human thick ascending limb of Henle [J].
Blanchard, A ;
Jeunemaitre, X ;
Coudol, P ;
Dechaux, M ;
Froissart, M ;
May, A ;
Demontis, R ;
Fournier, A ;
Paillard, M ;
Houillier, P .
KIDNEY INTERNATIONAL, 2001, 59 (06) :2206-2215
[4]  
Bolino A., 1993, European Journal of Human Genetics, V1, P269
[5]   The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal [J].
Bolland, M. J. ;
Ames, R. W. ;
Horne, A. M. ;
Orr-Walker, B. J. ;
Gamble, G. D. ;
Reid, I. R. .
OSTEOPOROSIS INTERNATIONAL, 2007, 18 (04) :479-486
[6]   RELATION BETWEEN DOSE OF BENDROFLUAZIDE, ANTIHYPERTENSIVE EFFECT, AND ADVERSE BIOCHEMICAL EFFECTS [J].
CARLSEN, JE ;
KOBER, L ;
TORPPEDERSEN, C ;
JOHANSEN, P .
BRITISH MEDICAL JOURNAL, 1990, 300 (6730) :975-978
[7]   High citrate diet delays progression of renal insufficiency in the ClC-5 knockout mouse model of Dent's disease [J].
Cebotaru, V ;
Kaul, S ;
Devuyst, O ;
Cai, H ;
Racusen, L ;
Guggino, WB ;
Guggino, SE .
KIDNEY INTERNATIONAL, 2005, 68 (02) :642-652
[8]   Phenotype and genotype of Dent's disease in three Korean boys [J].
Cheong, HI ;
Lee, JW ;
Zheng, SH ;
Lee, JH ;
Kang, JH ;
Kang, HG ;
Ha, IS ;
Lee, SJ ;
Choi, Y .
PEDIATRIC NEPHROLOGY, 2005, 20 (04) :455-459
[9]   Renal manifestations of Dent disease and Lowe syndrome [J].
Cho, Hee Yeon ;
Lee, Bum Hee ;
Choi, Hyun Jin ;
Ha, Il Soo ;
Choi, Yong ;
Cheong, Hae Il .
PEDIATRIC NEPHROLOGY, 2008, 23 (02) :243-249
[10]   Renal chloride channel, CLCN5, mutations in Dent's disease [J].
Cox, JPD ;
Yamamoto, K ;
Christie, PT ;
Wooding, C ;
Feest, T ;
Flinter, FA ;
Goodyer, PR ;
Leumann, E ;
Neuhaus, T ;
Reid, C ;
Williams, PF ;
Wrong, O ;
Thakker, RV .
JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (09) :1536-1542